Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

DelMar and Guangxi Wuzhou Pharma to Develop Cancer Drug

publication date: Oct 29, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
DelMar Pharma of Canada and Guangxi Wuzhou Pharma will expand their collaboration by developing new indications for VAL-083 in China. Wuzhou Pharmaceuticals will be the exclusive supplier of VAL-083, which it calls DAG for Injection. It sells the drug in China as an approved treatment for leukemia and lung cancer. DelMar will be responsible for developing new indications for the drug. In the US, DelMar is conducting a clinical trial of DAG in patients with the most aggressive form of brain cancer, refractory glioblastoma multiforme (GBM). More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...